BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 15, 2026
Home » Money raised by biotech: 2017 vs. 2016

Money raised by biotech: 2017 vs. 2016

Oct. 27, 2017

Article reprints

To read more on related topics, click on one of the words below.

BioWorld

    • Related Articles

      Money raised by biotech: 2017 vs. 2016

      Money raised by biotech: 2017 vs. 2016

      Money raised by biotech: 2017 vs. 2016

    Popular Stories

    • Today's news in brief

      BioWorld
      BioWorld briefs for June 12, 2026.
    • Neck exam

      Ethyreal launches to treat the underlying cause of Graves’, TED

      BioWorld
      Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
    • Illustration of Lactobacillus

      Microbiota modulates the antidepressant effects of GLP-1 analogues

      BioWorld Science
      Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
    • Genome sequence map

      EHA 2026: With new lenses, a changing view on pediatric cancers

      BioWorld
      In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
    • Microscopic image of chronic myeloid leukemia

      Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

      BioWorld
      Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
    • BioWorld
      • Today's news
      • Analysis and data insight
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Medical technology
      • Newco news
      • Opinion
      • Regulatory
    • BioWorld Science
      • Today's news
      • Biomarkers
      • Cancer
      • Conferences
      • Endocrine/metabolic
      • Immune
      • Infection
      • Neurology/psychiatric
      • NME Digest
      • Patents
    • BioWorld Asia
      • Today's news
      • Analysis and data insight
      • Australia
      • China
      • Clinical
      • Deals and M&A
      • Financings
      • Newco news
      • Regulatory
      • Science
    • More
      • About
      • Advertise with BioWorld
      • Archives
      • Article reprints and permissions
      • Contact us
      • Cookie policy
      • Copyright notice
      • Data methodology
      • Infographics: Dynamic digital data analysis
      • Index insights
      • Podcasts
      • Privacy policy
      • Share your news with BioWorld
      • Staff
      • Terms of use
      • Topic alerts
    Follow Us

    Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing